Insider Selling: Denali Therapeutics (NASDAQ:DNLI) Insider Sells $64,881.92 in Stock

Denali Therapeutics Inc. (NASDAQ:DNLI) insider Alexander Schuth sold 2,768 shares of the company’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $23.44, for a total transaction of $64,881.92. Following the completion of the transaction, the insider owned 278,995 shares in the company, valued at approximately $6,539,642.80. This trade represents a 0.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Denali Therapeutics Stock Performance

DNLI stock traded down $0.05 during trading hours on Thursday, hitting $22.80. 1,727,974 shares of the stock were exchanged, compared to its average volume of 1,712,119. Denali Therapeutics Inc. has a 12 month low of $12.58 and a 12 month high of $27.30. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. The company has a 50-day simple moving average of $24.54 and a two-hundred day simple moving average of $21.80. The firm has a market capitalization of $3.64 billion, a P/E ratio of -8.03 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million for the quarter, compared to analysts’ expectations of $2.15 million. During the same period in the prior year, the company earned ($0.72) earnings per share. On average, analysts forecast that Denali Therapeutics Inc. will post -2.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DNLI has been the topic of a number of research analyst reports. BTIG Research restated a “buy” rating and issued a $39.00 price target on shares of Denali Therapeutics in a research note on Monday, May 11th. JPMorgan Chase & Co. assumed coverage on Denali Therapeutics in a report on Monday, July 13th. They issued an “overweight” rating and a $29.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a report on Friday, July 17th. Sanford C. Bernstein reiterated a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Finally, Stifel Nicolaus set a $41.00 price target on Denali Therapeutics in a report on Monday, June 22nd. Fourteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $35.85.

Institutional Investors Weigh In On Denali Therapeutics

Hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its stake in Denali Therapeutics by 21.7% in the first quarter. Bank of America Corp DE now owns 1,134,183 shares of the company’s stock valued at $21,776,000 after acquiring an additional 202,039 shares during the last quarter. Great Lakes Advisors LLC bought a new position in shares of Denali Therapeutics in the second quarter valued at approximately $3,731,000. E. Ohman J or Asset Management AB bought a new stake in Denali Therapeutics during the second quarter valued at $4,115,000. Sei Investments Co. bought a new position in shares of Denali Therapeutics in the first quarter worth approximately $1,003,000. Finally, UBS Group AG raised its position in Denali Therapeutics by 19.5% during the fourth quarter. UBS Group AG now owns 2,404,704 shares of the company’s stock valued at $39,702,000 after purchasing an additional 392,351 shares in the last quarter. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.